SCHEMBL13798698

SCHEMBL13798698

CCN[C@H]1CC[C@H](OCCN2CCOCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.47
▸ EPHX2 P34913 3/20 0.44
▸ MCHR1 Q99705 1/20 0.38
▸ CD38 P28907 1/20 0.38
▸ MAPK1 P28482 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ SCN1A P35498 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ SCN2A Q99250 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ SCN3A Q9NY46 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13866421 0.85 NPC1 (0.46) NPC1EPHX2MCHR1CD38MAPK1
SCHEMBL14984925 0.85 NPC1 (0.46) NPC1EPHX2MCHR1CD38MAPK1
SCHEMBL12820372 0.82 NPC1 (0.46) NPC1EPHX2MCHR1CD38ALDH1A1
SCHEMBL12403926 0.81 EPHX2 (0.43) NPC1EPHX2MCHR1CD38CYP1A2
SCHEMBL18855748 0.81 NPC1 (0.71) NPC1EPHX2MCHR1ALDH1A1CYP1A2
SCHEMBL8263002 0.80 NPC1 (0.50) NPC1EPHX2MCHR1MAPK1ALDH1A1
SCHEMBL13993536 0.80 NPC1 (0.50) NPC1EPHX2MCHR1MAPK1ALDH1A1
SCHEMBL9703528 0.79 NPC1 (0.75) NPC1EPHX2MCHR1ALDH1A1CYP1A2
SCHEMBL13086520 0.78 NPC1 (0.52) NPC1EPHX2MCHR1MAPK1ALDH1A1
SCHEMBL14652222 0.76 NPC1 (0.46) NPC1EPHX2MCHR1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163493-A9 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2009-06-25 — — US disclosed
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor SERENEX, INC. 2008-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163493-A9 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor HSP90AA1, HSP90AB1, HSPA4 NPC1 2824/4885EPHX2 3152/4885MCHR1 2678/4885
US-20080096887-A1 cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor HSP90AA1, HSP90AB1, HSPA4 NPC1 2824/4885EPHX2 3152/4885MCHR1 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback